Replies to post #99260 on Biotech Values

[DewDiligence]

Ok—I’ll add ACHN to the compilation. I may remove GILD since it no longer appears to be a serious contender.

[DewDiligence]

Who’s Who in All-Oral HCV Programs

[Updates:
new entry for ACHN;
new entry for VRUS’ dual-nuke cocktail;
removed GILD’s program, which is dead in the water (#msg-52470566);
added clinicaltrials.gov link for IDX184+IDX320 DDI study.]

 
          Protease     Other      Non-PI    Dosing 
 Company  Inhibitor   Compound    Class    Frequency  Link 
 VRTX     Telaprevir  VX-222     non-nuke    BID      http://clinicaltrials.gov/ct2/show/NCT01080222 
 Roche    ITMN-191    RG7128       nuke     TID/BID   http://clinicaltrials.gov/ct2/show/NCT00801255 
 BMY      BMS-650032  BMS-790052   NS5A      BID      http://clinicaltrials.gov/ct2/show/NCT01012895 
 B-I      BI 201335   BI 207127  non-nuke   TID/BID   http://clinicaltrials.gov/ct2/show/NCT01132313 
 IDIX     IDX320      IDX184       nuke       qD†     http://clinicaltrials.gov/ct2/show/NCT01157104 
 ACHN     ACH-1625    ACH-2928     NS5A       qD      *       
 VRUS       n/a       PSI-7977   nuke/nuke    qD      * 
                     +PSI-938 

*All-oral trial has not started.
†BID for genotype-3 only.